Anti-TDP-43 Binding Molecules and Uses Thereof
Summary
The USPTO granted Patent No. US12600766B2 to AC Immune SA covering anti-TDP-43 specific binding molecules, including antibodies and antigen-binding fragments, for diagnosing, preventing, and treating diseases associated with TDP-43 aggregates. The patent lists 15 claims and names Tamara Seredenina, Tamar Magdalena Ziehm, and Tariq Afroz as inventors. The filing date was May 22, 2020, under Application No. 17613444.
What changed
The USPTO granted Patent No. US12600766B2 to AC Immune SA for anti-TDP-43 binding molecules including antibodies and antigen-binding fragments. The patent covers methods for diagnosing, preventing, alleviating, and treating diseases associated with TDP-43 aggregates, including Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE). The grant confers exclusive rights in the US for the remaining patent term.
For pharmaceutical and biotechnology companies developing TDP-43 targeting therapies, this patent creates potential IP barriers. Competitors may need to seek licenses, design around the claims, or assess freedom to operate before advancing similar programs to market.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Anti-TDP-43 binding molecules and uses thereof
Grant US12600766B2 Kind: B2 Apr 14, 2026
Assignee
AC Immune SA
Inventors
Tamara Seredenina, Tamar Magdalena Ziehm, Tariq Afroz
Abstract
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
CPC Classifications
C07K 16/18 C07K 2317/34 C07K 2317/92 C07K 2317/52 A61P 25/00 A61P 25/02 A61P 25/28 G01N 33/6896 G01N 2800/28 G01N 2800/2814 G01N 2800/2821 G01N 2800/2835 G01N 2800/2878 G01N 2800/52 G01N 33/6893 A61K 2039/505
Filing Date
2020-05-22
Application No.
17613444
Claims
15
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.